Chester County News and Community Website
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has received U.S. Food and Drug Administration Orphan Drug Designation for its lead pulmonary arterial hypertension drug candidate, a regulatory milestone that …
Inhibikase Wins FDA Orphan Status for PAH Drug Candidate Read More WASHINGTON, D.C. — The Food and Drug Administration rolled out a rapid-fire series of moves this month that could reshape how Americans manage chronic disease, treat rare and life-threatening blood …
FDA’s Week of Breakthroughs: New Gene Therapy, New Antibiotics, New Rules Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for all currently approved BCMA- and CD19-directed …
FDA Removes REMS Requirements for CAR T Cell Therapies, Boosting Patient Access Read More
BERWYN, PA — AscellaHealth has announced its role as a Silver Sponsor of the World Orphan Drug Congress USA (WODC), which will convene from April 22-24, 2025, at the Boston …
AscellaHealth to Sponsor and Lead Key Discussion at World Orphan Drug Congress USA 2025 Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has issued a series of important updates addressing healthcare challenges, regulatory actions, and emerging safety concerns, with implications for medical …
Health Alert: FDA Exposes Life-Threatening Risks, Device Shortages, and Food Safety Failures You Need to Know Now! Read More
KING OF PRUSSIA, PA — SEED Therapeutics Inc. has announced that its molecular glue therapy, ST-01156, has been granted Rare Pediatric Disease and Orphan Drug designations by the U.S. Food and …
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 Read More
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small …
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment Read More